A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)V. Gruenwald,C. Gruellich,P. Ivanyi,M. Wirth,P. Staib,M. Schostak, P. Dargatz,L. Mueller,M. Metz,L. Bergmann,M. K. Welslau, P. Schuett,M-R. Rafiyan,E. Hellmis,A. Hinke,J. Meiler, T. Kretz,W. C. Loidl, A. Floercken,T. SteinerAnnals of Oncology（2019）引用 0|浏览17暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
